Literature DB >> 18475040

Dose-dependent effects of recombinant human interleukin-11 on the systemic hemodynamic function and urination.

Kaneatsu Honma1, Nancy L Koles, Hasan B Alam, James C Keith, Matthew Pollack.   

Abstract

The purpose of this study was to determine whether recombinant human interleukin-11 (rhIL-11) could dose-dependently improve the hemodynamic function. Using a swine hemorrhagic shock model, rhIL-11 was given at the beginning of resuscitation. The animals were randomized to receive a single dose of rhIL-11 (5, 20, or 50 microg/kg, group I to III for respectively) or saline (group IV). Blood, urine and both pleural and peritoneal effusion were thus obtained and analyzed. The mean arterial pressure (MAP) was higher post-resuscitation (PR) in group III (62.9+/-8.2 mmHg) than in groups I, II and IV (54.9+/-1.7, 53.9+/-4.3, 55.9+/-9.4 mmHg, respectively) (P<0.01). The urine output (I: 999+/-428, II: 1249+/-180, III: 1434+/-325, IV: 958+/-390 ml) and the cardiac output (CO) (I: 3.01+/-0.66, II: 3.30+/-0.49, III: 3.43+/-0.57, IV: 2.73+/-0.49 L/min.) increased in a dose dependent manner of rhIL-11. CO level and urine output were significantly higher in group III than in group IV (P<0.05). In addition, the volume of third space fluid loss (pleural and peritoneal effusion) of group III was significantly lower than other groups (I: 157+/-32, II: 138+/-32, III: 82+/-21, IV: 125+/-32 ml) (P<0.05). In conclusion, even a low dose of rhIL-11 improved the hemodynamic functions dose-dependently in a porcine model of hemorrhagic shock, although the relationship did not demonstrate a simple linearity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18475040     DOI: 10.2739/kurumemedj.54.73

Source DB:  PubMed          Journal:  Kurume Med J        ISSN: 0023-5679


  1 in total

1.  IL-11 promotes the treatment efficacy of hematopoietic stem cell transplant therapy in aplastic anemia model mice through a NF-κB/microRNA-204/thrombopoietin regulatory axis.

Authors:  Yan Wang; Zhi-Yun Niu; Yu-Jie Guo; Li-Hua Wang; Feng-Ru Lin; Jing-Yu Zhang
Journal:  Exp Mol Med       Date:  2017-12-08       Impact factor: 8.718

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.